Catalyst
Slingshot members are tracking this event:
BioXcel's (BTAI) Phase 2 update of BXCL701 and Keytruda in Neuroendocrine Prostate Cancer (tNEPC) to be presented at ASCO GU February 11, 2021 at 8:00 a.m EST.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BTAI | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 11, 2021
Occurred Source:
https://meetinglibrary.asco.org/record/194900/abstract
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bxcl701, Keytruda, Neuroendocrine Prostate Cancer, Asco
